143 related articles for article (PubMed ID: 16116483)
1. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
[TBL] [Abstract][Full Text] [Related]
2. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
[TBL] [Abstract][Full Text] [Related]
3. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
[TBL] [Abstract][Full Text] [Related]
4. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
5. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
[TBL] [Abstract][Full Text] [Related]
6. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
7. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
8. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
10. Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
Kresinsky A; Schnöder TM; Jacobsen ID; Rauner M; Hofbauer LC; Ast V; König R; Hoffmann B; Svensson CM; Figge MT; Hilger I; Heidel FH; Böhmer FD; Müller JP
Oncogene; 2019 Jun; 38(24):4773-4787. PubMed ID: 30820040
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence and clinical significance of FLT3 internal tandem duplication mutation in acute leukemia].
Wang LH; Zhou CL; Zhang XW; Chen S; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):393-6. PubMed ID: 15355689
[TBL] [Abstract][Full Text] [Related]
12. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
14. Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation.
Bailey EJ; Duffield AS; Greenblatt SM; Aplan PD; Small D
Comp Med; 2013 Jun; 63(3):218-26. PubMed ID: 23759524
[TBL] [Abstract][Full Text] [Related]
15. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
16. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Kajiguchi T; Chung EJ; Lee S; Stine A; Kiyoi H; Naoe T; Levis MJ; Neckers L; Trepel JB
Leukemia; 2007 Dec; 21(12):2476-84. PubMed ID: 17851558
[TBL] [Abstract][Full Text] [Related]
17. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
18. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.
Kharazi S; Mead AJ; Mansour A; Hultquist A; Böiers C; Luc S; Buza-Vidas N; Ma Z; Ferry H; Atkinson D; Reckzeh K; Masson K; Cammenga J; Rönnstrand L; Arai F; Suda T; Nerlov C; Sitnicka E; Jacobsen SE
Blood; 2011 Sep; 118(13):3613-21. PubMed ID: 21813452
[TBL] [Abstract][Full Text] [Related]
19. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.
Reddy PN; Sargin B; Choudhary C; Stein S; Grez M; Müller-Tidow C; Berdel WE; Serve H; Brandts CH;
Blood; 2012 Aug; 120(8):1691-702. PubMed ID: 22517899
[TBL] [Abstract][Full Text] [Related]
20. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]